

**ARTICLES**

1. Relli V., Trerotola M., Guerra E. and **Alberti S.** Distinct lung cancer subtypes associate to distinct drivers of tumor progression. *Oncotarget* (in press) (2018). IF = 5.008
2. Avellini C., Licini C., Lazzarini R., Gesuita R., Guerra E., Tossetta G., Castellucci C., Giannubilo S.R., Procopio A., **Alberti S.**, Mazzucchelli R., Olivieri F. and Marzioni D. The trophoblastic cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. *Oncotarget* 8(35): 58642-58653 (2017). IF = 5.008
3. Guerra E., Piantelli M. and **Alberti S.** Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. *Science Transl. Med.* 8:350 350le2 (2016). IF = 16.264
4. Guerra E., Cimadamore A., Simeone P., Vacca G., Lattanzio R., Botti G., Gatta V., D' Aurora M., Simionati B., Piantelli M. and **Alberti S.** p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. *BMC Cancer* (2016) 16:649 (<https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2713-3>). IF = 3.360
5. **Alberti S.** Native, sequential protein folding via anchored N- and C- protein termini. *Proc. Natl. Acad. Sci. USA* 113: 23 E3189-91 (2016) ([www.pnas.org/cgi/doi/10.1073/pnas.1602454113](http://www.pnas.org/cgi/doi/10.1073/pnas.1602454113) PNAS Early Edition 1-3). IF = 9.674
6. Simeone P. and **Alberti S.** HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer. *J. Natl. Cancer Inst.* 108(8): djw143 (2016). IF = 12.583
7. Guerra E., Trerotola M., Tripaldi R., Aloisi A.L., Simeone P., Sacchetti A., Relli V., D' Amore A., La Sorda R., Lattanzio R., Piantelli M. and **Alberti S.** Trop-2 induces tumor growth through Akt and determines sensitivity to Akt inhibitors. *Clin. Cancer Res.* 22 (16) 4197-4205 (2016). IF = 9.619
8. Vergara D., Simeone P., Julien F., Trerotola M., Giudetti A., Capobianco L., Tinelli A., Bellomo C., Fournier I., Antonio G., **Alberti S.**, Salzet M., Maffia M. Translating epithelial mesenchymal transition markers into the clinic: novel insights from proteomics *EuPA Open Proteomics* 10: 31-41 (2016).
9. Brown D.N., Caffa I., Cirmena G., Piras D., Garuti A., Gallo M., **Alberti S.**, Nencioni A., Ballestrero A., Zoppoli G. Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. *Sci. Reports* Jan 18;6:19435 (2016). IF = 5.578
10. Vergara D., Simeone P., Latorre D., Cascione F., Leporatti S., Trerotola M., Anna Giudetti M., Capobianco L., Lunetti P., Rizzello A., Rinaldi R., **Alberti S.**, Maffia M. Proteomics analysis of E-cadherin knockdown in epithelial breastcancer cells. *J. Biotechnol.* 202: 3-11 (2015). IF = 2.884
11. Trerotola M., Relli V., Simeone P. and **Alberti S.** Epigenetic inheritance and the missing heritability. *Human Genomics-BMC* 9 (17): 1-12 (2015). IF = 2.15

12. Antolini L., Biganzoli E., Querzoli P., Piantelli M. and **Alberti S.** Lymph nodes micrometastases do impact on breast cancer outcome. *J. Clin. Oncol.* 33 (33): 3977-8 (2015). IF = 18.430
13. Li Y., Melnikov A. A., Levenson V., Guerra E., Simeone P., **Alberti S.** and Deng Y. A seven-gene CpG-island methylation panel predicts breast cancer progression. *BMC Cancer* 15 (417): 1-12 (2015) (**corresponding author**). IF = 3.360
14. Simeone P., Trerotola M., Urbanella A., Lattanzio R., Ciavardelli D., Di Giuseppe F., Eleuterio E., Sulpizio M., Eusebi V., Pession A., Piantelli M. and **Alberti S.** A unique four-hub protein cluster associates to glioblastoma progression. *PLoS One* 9 (7): 1-17 e103030 (2014). **Highlights - Malkki H. - Simeone P. and Alberti S. - Proteomic profiling could facilitate glioblastoma diagnosis. Nature Reviews Neurology (10): 2 (2014).** IF: 14.103
15. Simeone P. and **Alberti S.** Epigenetic heredity of human height. *Phys. Rep.* 2 (6): 1-20 e12047 (2014).
16. Ambrogi F., Fornili M., Boracchi P., Trerotola M., Relli V., Simeone P., La Sorda R., Lattanzio R., Querzoli P., Pedriali M., Piantelli M., Biganzoli E. and **Alberti S.** Trop-2 is a determinant of breast cancer survival. *PLoS One* 9 (10): 1-11 e96993 (2014). Erratum in: *PLoS One*. 2014;9(10):e110606. IF = 3.534
17. Vergara D., Simeone P., del Boccio P., Toto C., Pieragostino D., Tinelli A., Acierno R., **Alberti S.**, Salzet M., Giannelli G., Sacchetta P., Maffia M. Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. *Mol Biosyst.* 9 (6): 1127-38 (2013). IF = 3.183
18. Tripaldi R., Stuppia L. and **Alberti S.** Human height genes and cancer. *BBA Reviews on Cancer* 1836 (1): 27-41 (2013). IF = 7.584
19. Lattanzio R., Marchisio M., La Sorda R., Tinari N., Falasca M., **Alberti S.**, Miscia S., Ercolani C., Di Benedetto A., Perracchio L., Melucci E., Iacobelli S., Mottolose M., Natali P. G. and Piantelli M. Overexpression of activated phospholipase C $\gamma$ 1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy. *Int. J. Cancer* 132: 1022-31 (2013). IF = 5.007
20. Guerra E., Trerotola M., Aloisi A.L., Tripaldi R., Vacca G., La Sorda R., Lattanzio R., Piantelli M. and **Alberti S.** The Trop-2 signalling network in cancer growth *Oncogene* 32: 1594-1600 (2013). IF = 8.559
21. Ambrogi F., Fornili M., **Alberti S.**, Querzoli P., Piantelli M., Pedriali M., Boracchi P., Biganzoli E. and Coradini D. EpCAM Expression is an Indicator of Increased Incidence of Relapse in p53-Positive Breast Cancer. *Cancer Clin. Oncol.* 2 (1): 41-50 (2013).
22. Trerotola M., Cantanelli P., Guerra E., Tripaldi R., Aloisi A.L., Bonasera V., Lattanzio R., de Lange R., Weidle U.H., Piantelli M. and **Alberti S.** Up-regulation of Trop-2 quantitatively stimulates human cancer growth. *Oncogene* 32: 222-233 (2013). IF = 8.559

23. Guerra E., Lattanzio R., La Sorda R., Dini F., Piantelli M., Tiboni G.M. and **Alberti S.** mTrop1/EpCAM knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/ $\beta$ -catenin. *PLoS One* 7 (11): 1-9 e49302 (2012). IF = 3.534
24. **Alberti S.**, Ambroggi F., Boracchi P., Fornili M., Querzoli P., Pedriali M., La Sorda R., Lattanzio R., Tripaldi R., Piantelli M., Biganzoli E. and Coradini D. Cytoplasmic Trop-1/EpCAM over-expression is associated with a favorable outcome in node-positive breast cancer *Jpn. J. Clin. Oncol.* 42 (12):1128-37 (2012). IF = 1.747
25. Trerotola M., Li J., **Alberti S.** and Languino L.R. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the  $\beta$ 1 integrin-RACK1 axis. *J. Cell Physiol.* 227(11): 3670-7 (2012). IF = 3.874
26. Plebani R., Oliver G.R., Trerotola M., Guerra E., Cantanelli P., Emerson A., Harkin P.D., Kennedy R.D. and **Alberti S.** Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA. *Neoplasia* 14 (11): 1087-1096 (2012). IF = 5.398
27. Vergara D., Simeone P., Toraldo D., Del Boccio P., Vergaro V., Leporatti S., Pieragostino D., Tinelli A., De Domenico S., **Alberti S.**, Urbani A., Salzet M., Santino A. and Maffia M. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. *Mol Biosyst.* 8: 1078–87 (2012). IF = 3.183
28. Biganzoli E., Coradini D., Ambroggi F., Garibaldi J., Lisboa P., Soria D., Green A., Pedriali M., Piantelli M., Querzoli P., Demicheli R., Boracchi P., Nenci I., Ellis I. and **Alberti S.** p53 Status Identifies Two Distinct Subgroups of Triple-Negative Breast Cancers. *Jpn. J. Clin. Oncol.* 41 (2): 172-9 (2011). IF = 1.747
29. Querzoli P., Coradini D., Pedriali M., Boracchi P., Ambroggi F., Raimondi E., La Sorda R., Lattanzio R., Rinaldi R., Lunardi M., Frasson C., Modesti F., Ferretti S., Piantelli M., Iacobelli S., Biganzoli E., Nenci I. and **Alberti S.** An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. *Br. J. Cancer* 103 (12): 1835-9 (2010). IF = 4.817
30. Pannellini T., Iezzi M., Liberatore M., Sabatini F., Iacobelli S., Rossi R., **Alberti S.**, Di Ilio C., Vitaglione P., Fogliano V. and Mauro Piantelli M. A dietary tomato supplement prevents prostate cancer in TRAMP mice. *Cancer Prev. Res.* 3(10): 1284-91(2010). IF = 5.269
31. Sukhthankar M., **Alberti S.** and Seung Joon Baek S. J. (-)-Epigallocatechin-3-Gallate (EGCG) Post-transcriptionally and Post-translationally Suppresses the Cell Proliferative Protein Trop-2 in Human Colorectal Cancer Cells. *Anticancer Res.* 30 (7): 2497-503 (2010). IF = 1.872
32. Trerotola M., Rathore S., Goel H.L., Li J., Alberti S., Piantelli M., Adams D., Jiang Z. and Languino L. CD133, Trop-2 and  $\alpha$ 2 $\beta$ 1 Integrin Surface Receptors as Markers of Putative Human Prostate Cancer Stem Cells. *Am. J. Transl. Res.* 2 (2): 135-44 (2010). IF = 3.226
33. Biganzoli E., Pedriali M., Querzoli P., Nenci I., Iacobelli S., Piantelli M. and **Alberti S.** Sentinel Node and Bone Marrow Micro and Nanometastases. *Curr. Breast Cancer Rep.* 2: 96–106 (2010).

34. Trerotola M., Guerra E. and **Alberti S.** Efficacy and safety of anti-Trop antibodies. *BBA Rev. Cancer* 1805: 119–120 (2010). IF = 7.584
35. Weidle U. H., Evtimova V., **Alberti S.**, Guerra E., Fersis N. and Kaul S. Cell Growth Stimulation by CRASH, an Asparaginase-like Protein Overexpressed in Human Tumors and Metastatic Breast Cancers. *Anticancer Res.* 29: 951-964 (2009). IF = 1.872
36. Tinari N., Lattanzio R., Querzoli P., Natoli C., Grassadonia A., **Alberti S.**, Hubalek M., Reimer D., Nenci I., Bruzzi P., Piantelli M. and Iacobelli S., on behalf of the Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO). High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. *Int. J. Cancer* 124: 333–338 (2009). IF = 5.007
37. Rossi C., Di Lena A., Lasorda R., Lattanzio R., Antolini L., Patassini C., Piantelli M. and **Alberti S.** Intestinal tumour chemoprevention with the antioxidant liponic acid stimulates the growth of breast cancer. *Eur. J. Cancer* 44: 2696–2704 (2008). IF = 4.819
38. Guerra E., Trerotola M., Dell' Arciprete R., Bonasera V., Palombo B., El-Sewedy T., Ciccimarra T., Crescenzi C., Lorenzini F., Rossi C., Vacca G., Lattanzio R., Piantelli M. and **Alberti S.** A bi-cistronic Cyclin D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. *Cancer Res.* 68: (19): 8113-8121 (2008). IF = 9.122
39. Marabotti A., Spyraakis F., Facchiano A., Cozzini P., **Alberti S.**, Kellogg G.E., Mozzarelli A. Energy-based prediction of amino acid-nucleotide base recognition. *J. Comp. Chem.* 29(12): 1955-1969 (2008). IF = 3.601
40. Bonasera V., **Alberti S.** and A. Sacchetti A. Protocol for high-sensitivity/long linear-range spectrofluorimetric DNA quantification using ethidium bromide. *BioTechniques* 43 (2): 173-176 (2007) (**corresponding author**). IF = 2.754
41. Zanna P., Trerotola M., Vacca G., Bonasera V., Palombo B., Guerra E., Rossi C., Lattanzio R., Piantelli M. and **Alberti S.** Trop-1 are conserved growth stimulatory molecules that mark early stages of tumor progression. *Cancer* 110 (2): 452-464 (2007). IF = 4.901
42. Carletti E., Guerra E. and **Alberti S.** The forgotten variables of DNA array hybridization. *Trends Biotech.* 24 (10): 443-448 (2006). IF = 10.04
43. Querzoli P., Pedriali M., Rinaldi R., Lombardi A.R., Biganzoli E., Boracchi P., Ferretti S., Frasson C., Zanella C., Ghisellini S., Ambrogi F., Antolini L., Piantelli M., Iacobelli S., Marubini E., **Alberti S.** and Nenci I. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. *Clin. Cancer Res.* 12: 6696-6701 (2006) (**corresponding author**). **Plenary lecture, SABCS, San Antonio (TX) 14-17 Dec. 2006. Debated in Oncology News Int. (Feb. 2007). Presented in "Highlights from the 29th annual San Antonio Breast Cancer Symposium", 2007, p. 6. Debated in JNCI 99(10): 751-3 (2007).** IF = 9.619
44. Piantelli M., Rossi C., Iezzi M., La Sorda R., Iacobelli S., **Alberti S.** and Natali P.G. Flavonoids inhibit melanoma lung metastases by impairing tumor cell-endothelium interactions. *J. Cell Physiol.* 207: 23-29 (2006). IF = 3.874

45. Tinari N., Lattanzio R., Natoli C., Cianchetti E., Angelucci D., Ricevuto E., Ficorella C., Marchetti P., **Alberti S.**, Piantelli M., Iacobelli S. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. *Clin. Cancer Res.* 12(5):1501-1506 (2006). IF = 9.619
46. Ambrogi F., Biganzoli E., Querzoli P., Ferretti S., Boracchi P., **Alberti S.**, Marubini E., Nenci I. Molecular subtyping from traditional tumor marker profiles using parallel clustering methods. *Clin. Cancer Res.*12(3): 781-790 (2006). IF = 9.619
47. Cimoli G., Malacarne D., Ponassi R., Valenti M., **Alberti S.** and Parodi S. Meta analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic anti-neoplastic drugs. *Biochim. Biophys. Acta – Rev. Cancer* 1705: 103– 120 (2004). IF = 7.584
48. Romani A., Guerra E., Trerotola M. and **Alberti S.** Detection and analysis of spliced chimeric mRNAs in sequence databanks. *Nucl. Acids Res.* 31 (4 e17): 1-8 (2003). IF = 8.808
49. **Alberti S.** and Parodi S. Signaling proteins as targets of new anti-neoplastic drugs *Int. J. Biol. Markers* 18: 57-61 (2003). IF = 1.36
50. Guerra E., Vacca G., Palombo B. and Alberti S. Prognostic value of mutations of *TP53* and *RAS* genes in breast cancer. *Int. J. Biol. Markers* 18: 49-53 (2003). **IF = 1.36**
51. Nasr A. F., Nutini M., Palombo B., Guerra E. and **Alberti S.** Mutations of *TP53* induce loss of DNA methylation and amplification of the *TROP1* gene. *Oncogene* 22: 1668-77 (2003). IF = 8.559
52. Mangino G., Capri M. G., Barnaba V. and **Alberti S.** Presentation of native Trop-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. *Int. J. Cancer* 101(4):353-9 (2002) (**with cover picture of the issue**).
53. Sacchetti A., Subramaniam V., Jovin T. M. and **Alberti S.** Oligomerization of DsRed is required for the generation of a functional red fluorescent chromophore. *FEBS letters* 525 (1-3): 13-19 (2002). IF = 3.341
54. **Alberti S.** Trop molecules as targets for anti-tumor immunotherapy in man. *Tumori* 87: S5-8 (2001). IF = 1.09
55. Guerra E. and **Alberti S.** Molecular prognostic indicators for breast cancer. *Tumori* 87: S23-25 (2001). IF = 1.09
56. Mercuri A., Sacchetti A., De Benedetti L., Schiva T. and Alberti S. Green Fluorescent Flowers. *Plant Science* 161 (5) 961– 968 (2001) [corrigendum: *Plant Science* 162 (4) 647-654 (2002)]. **Debated in: Nature, 24 oct. 2001; Newsweek, 9 dec. 2001; Der Spiegel, nov. 2001; Max, dec. 2001; Il Venerdì di Repubblica dec. 2001; La Stampa, 3 gen. 2002; Il Secolo XIX, 14 nov. 2001; Imperia-San Remo, 14 nov. 2001; Flortecnici dec. 2001; Riviera-Cote d' Azur Zeitung, 1 jan. 2002.** IF = 4.114

57. Sacchetti A., El-Sewedy T., Nasr A. F. and **Alberti S.** Efficient GFP mutations profoundly affect mRNA transcription and translation rates. *FEBS letters* 9; 492(1-2): 151-5 (2001). IF = 3.341
58. Balzar M., Briaire-de Bruijn I.H., Rees-Bakker H.A.M., Prins F.A., Hellfrich W., de Leij L., Riethmuller G., **Alberti S.**, Warnaar S.O., Fleuren G.J., and Litvinov S.V. Epidermal Growth Factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophylic adhesions. *Mol. Cell. Biol.* 21(7): 2570-2580 (2001). IF = 5.036
59. Sacchetti A., Cappetti V., Marra P., Dell'Arciprete R., El-Sewedy T., Crescenzi C. and **Alberti S.** Green Fluorescent Protein variants fold differently in prokaryotic and eukaryotic cells. *J. Cell. Biochem.* 36: 117-128 (2001). IF = 3.368
60. Terrinoni A., Dell' Arciprete R., Fornaro M., Stella M. and **Alberti S.** The Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. *Genes Chromosomes Cancer* 31(3): 209-220 (2001). IF = 3.836
61. Calabrese G., Crescenzi C., Morizio E., Palka G., Guerra E., **Alberti S.** Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of the TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. *Cytogenet. Cell Genet.* 92(1-2):164-5 (2001). (Now "Cytogenetic and Genome Research") IF = 1.905
62. Ciccarelli F., Acciarito A. and **Alberti S.** Large and diverse numbers of human diseases with HIKE mutations. *Hum. Mol. Genet.* 9:1001-1007 (2000). IF = 6.677
63. Polishchuk R.S., Polishchuk E.V., Marra P., **Alberti S.**, Buccione R., Luini A. and Mironov A. Correlative light-electron microscopy reveals the tubular-saccular ultrastructure of carriers operating between Golgi apparatus and plasma membrane. *J. Cell. Biol.* 148: 45-58 (2000). IF = 9.688
64. Sacchetti A., Ciccocioppo R. and **Alberti S.** The Molecular Determinants of the Efficiency of Green Fluorescent Protein Mutants. *Histol. Histopathol.* 15 (1): 101-107 (2000). IF = 2.236
65. **Alberti S.** The evolution of the genetic code, protein synthesis and nucleic acids replication. *Cell. Mol. Life Sci.* 56: 85:93 (1999). IF = 5.856
66. Sacchetti A. and **Alberti S.**, Protein tags enhance GFP folding in eukaryotic cells. *Nature Biotechnology* 17: 1046 (1999). IF = 43.113
67. Spanò S., Silletta M. G., Colanzi A., **Alberti S.**, Fiucci G., Valente C., Fusella A., Salmona M., Mironov A., Luini A., Corda D. Molecular cloning and functional characterization of brefeldin A-ADP-ribosylated substrate. A novel protein involved in the maintenance of the Golgi structure. *J. Biol. Chem.* 274 (25): 17705-10 (1999). IF = 4.6
68. Sacchetti A., Crescenzi C., Cappetti V., Celli N., Rotilio D. and **Alberti S.** Red GFP and endogenous porphyrins. *Curr. Biol.* 9 (11): 391-3 (1999). IF = 9.916

69. **Alberti S.** HIKE, a candidate protein binding site for PH domains, is a major regulatory region of Gb proteins. *Proteins* 35 (3): 360-3 (1999). IF = 2.921
70. **Alberti S.** Distinguishing ulcerative colitis from autoimmunity. *Mol. Med. Today* 4: 188 (1998). (Now "Trends in Molecular Medicine") IF = 10.11
71. Ripani E., Sacchetti A., Corda D. and **Alberti S.** The human Trop-2 is a tumor-associated calcium signal transducer. *Int. J. Cancer* 76: 671-676 (1998). IF = 5.007
72. **Alberti S.** A Phosphoinositide-binding Sequence is shared by PH Domain Target Molecules. - A Model for the Binding of PH Domains to Proteins. *Proteins* 31: 1-9 (1998). IF = 2.921
73. El-Sewedy T., Fornaro M. and **Alberti S.** Cloning of the mouse Trop2 gene - Conservation of a PIP2-binding sequence in the cytoplasmic domain of Trop-2. *Int. J. Cancer* 75: 324-331 (1998). IF = 5.007
74. Ciccocioppo R, Dell'Arciprete R, Marra P, **Alberti S.** Comparative analysis of wildtype and mutant forms of GFP. *Eur J Histochem.* 41 Suppl 2:97-8 (1997). IF = 2.237
75. **Alberti S.** The origin of the genetic code and of protein synthesis. *J. Mol. Evol.* 45 (4): 352-358 (1997). IF = 1.863
76. Alberti S. Novel drugs and strategies for gastrointestinal disorders. Meeting report. IBC conference "Gastrointestinal disorders: current understanding, new approaches to prevention and treatment". Royal Society, London, UK. June 23-24 (1997). *Mol. Med. Today* 3 (8): 416-417 (1997). (Now "Trends in Molecular Medicine") IF = 10.11
77. Ciccocioppo R., Capri M. G. and **Alberti S.** Detection of the Receptor for the Human urokinase-type Plasminogen Activator using Fluoresceinated uPA. *J. Histochem. Cytochem.* 45: 1307-1313 (1997). IF = 2.403
78. Guillaudeux T., Gomez E., Onno M., Drénou B., Segretain D., **Alberti S.**, Lejeune H., Fauchet R., Jégou B. and Le Bouteiller P. Expression of HLA class I genes in meiotic and post-meiotic human spermatogenic cells. *Biol. Reproduct.* 55: 99-110 (1996). IF = 3.451
79. **Alberti S.** A high affinity T cell receptor? *Immunol. Cell Biol.* 74: 292-297 (1996). IF = 4.205
80. **Alberti S.** Development of ulcerative colitis: evidence from animal models. *Mol. Med. Today* 2: 272-274 (1996). (Now "Trends in Molecular Medicine") IF = 10.11
81. Dell' Arciprete R., Stella M., Fornaro M., Ciccocioppo R., Capri M. G., Naglieri A. M. and **Alberti S.** High efficiency expression gene cloning by flow cytometry. *J. Histochem. Cytochem.* 44: 629-640 (1996). IF = 2.403
82. Fornaro M., Dell' Arciprete R., Stella M., Bucci C., Nutini M., Capri M. G. and **Alberti S.** Cloning of the gene encoding Trop-2, a cell surface glycoprotein expressed by human carcinomas. *Int. J. Cancer* 62: 610-618 (1995). IF = 5.007

83. **Alberti S.**, Nutini M. and Herzenberg L. A. DNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene. *Proc. Natl. Acad. Sci. USA* 91: 5833 (1994). IF = 9.809
84. Vermeer L. A., de Boer N. K., Bucci C., Bos N. A., Kroese F. G. M. and **Alberti S.** MRC OX19 recognizes the rat CD5 surface glycoprotein, but does not provide evidence for the presence of a distinct CD5 positive B cell population in the rat. *Eur. J. Immunol.* 24: 585 (1994). IF = 4.518
85. Kaufmann R., Hainzl A., Sterry W., Sonnenberg A., **Alberti S.** and Klein C. E. Klein Integrin receptor molecules in human skin xenografts are selectively bound by intravenously applied anti-integrin antibodies. *Arch. Dermatol. Res.* 286: 6 (1994). IF = 2.27
86. Schön M. P., Schön M., Mattes M. J., Stein R., Weber L., **Alberti S.** and Klein C. E. Biochemical and immunological characterization of the human carcinoma-associated antigen MH99/KS1/4. *Int. J. Cancer* 55: 988 (1993). IF = 5.007
87. Anichini A., Mortarini R., **Alberti S.**, Mantovani A. and Parmiani G. T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis. *Int. J. Cancer* 53: 994-1001 (1993). IF = 5.007
88. **Alberti S.**, Miotti S., Stella M., Klein C.E., Fornaro M., Ménard S. and Colnaghi M. I. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: Formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. *Hybridoma* 11: 539 (1992). IF = 0.244
89. Miotti S., **Alberti S.**, Mantovani L., Facheris P., Fornaro M., Stella M., Ménard S., Canevari S. and Colnaghi M.I. Membrane association and shedding of the GPI-anchored CaMOv18 antigen in human ovary carcinoma cells. *Int. J. Cancer* 51: 499 (1992). IF = 5.007
90. Jonjic N., **Alberti S.**, Bernasconi S., Peri G., Jilek P., Anichini A., Parmiani G. and Mantovani A. Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer. *Eur. J. Immunol.* 22: 2255-2260 (1992). IF = 4.518
91. Vermeer L., Bos N., Bucci C., Kroese F. and **Alberti S.** Molecular cloning of the rat CD5 gene. *Ann. N. Y. Acad. Sci.* 651: 82 (1992). IF = 4.313
92. Lalor P., Bucci C., Fornaro M., Rattazzi M.C., Nakauchi H., Herzenberg L.A. and **Alberti S.** Molecular cloning, reconstruction and expression of the gene encoding the alpha chain of the bovine CD8 - Definition of three peptide regions conserved across species. *Immunology* 76: 95 (1992). IF = 3.735
93. **Alberti S.**, Bucci C., Fornaro M., Robotti A. and Stella M. Immunofluorescence Analysis in Flow Cytometry: Better Selection of Antibody-Labeled Cells after Fluorescence Overcompensation in the Red Channel. *J. Histochem. Cytochem.* 39: 701 (1991). IF = 2.403

94. **Alberti S.**, Miotti S., Fornaro M., Mantovani L., Walter S., Canevari S., Ménard S. and Colnaghi M. I. The Ca-MOv18 molecule, a cell surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. *Biochem. Biophys. Res. Comm.* 171: 1051 (1990). IF = 2.281
95. Toye P.G., Machugh N.D., Bensaid A.M., **Alberti S.**, Teale A.J. and Morrison W.I. Transfection into mouse L cells of genes encoding two serologically and functionally distinct bovine class I MHC molecules from a MHC-homozygous animal: evidence for a second class I locus in cattle. *Immunology* 70: 20 (1990). IF = 3.735
96. Klein C. E., Hartmann B., Schön M. P., Weber L. and **Alberti S.** Expression of a 38 kD cell surface glycoprotein in transformed human keratinocyte cell lines, basal cell carcinomas and epithelial germs. *J. Invest. Dermatol.* 95: 74 (1990). IF = 6.372
97. **Alberti S.** and Fornaro M. Higher transfection efficiency of genomic DNA purified with a guanidinium thiocyanate-based procedure. *Nucl. Acids Res.* 18 (2): 351 (1990). IF = 8.808
98. **Alberti S.** and Herzenberg L. A. DNA methylation prevents transfection of genes for specific surface antigens. *Proc. Natl. Acad. Sci. USA* 85: 8391 (1988). IF = 9.809
99. **Alberti S.**, Parks D. R. and Herzenberg L. A. A single laser method for subtraction of cell autofluorescence in flow cytometry. *Cytometry* 8: 114 (1987). IF = 3.066
100. **Alberti S.** and Herzenberg L. A. DNA transfection: gene regulation, gene amplification and gene cloning. *Juntendo Med. J.* 32 (4): 423 (1986).
101. **Alberti S.**, Filippeschi S., Spreafico F., Alberti E. and Colotta F. Metastatic growth of a murine tumor: evidence of dissemination to the lungs in the absence of subcutaneous growth. *Tumori* 72(4):345-50 (1986). IF = 1.09
102. **Alberti S.**, Colotta F., Spreafico F., Delia D., Pasqualetto E. and Luini W. Large granular lymphocytes from murine blood and intestinal epithelium: comparison of surface antigens, natural killer activity and morphology. *Clin. Immunol. Immunopathol.* 36: 227 (1985). (Now "Clinical Immunology") IF = 3.992
103. **Alberti S.**, Luini W., Pasqualetto E., Allegrucci M., Spreafico F., Patterson S., Grindley H., Alberti E. and Colotta F. Relationship between large granular lymphocytes and NK-1.2 + cells from normal and poli-IC treated mice. *Clin. Immunol. Immunopathol.* 36: 81 (1985). (Now "Clinical Immunology") IF = 3.992
104. Herzenberg L. A., Hsu C., **Alberti S.** and Kavathas P. Transfection and cloning of genes for membrane antigens using the FACS. *Med. Oncol. Tum. Pharmacother.* 1 (4): 219 (1984). IF = 0.944
105. **Alberti S.**, Stovel D. and Herzenberg L. A. Preservation of cells sorted individually onto microscope slides with a fluorescence-activated cell sorter. *Cytometry* 5: 644 (1984). IF = 3.066

106. Acero R., Polentarutti N., Bottazzi B., **Alberti S.**, Ricci M. R., Bizzi A. and Mantovani A. Effect of hydrocortisone on the macrophage content, growth and metastasis of transplanted murine tumors. *Int. J. Cancer* 33: 95 (1984). IF = 5.007
107. Altavilla G., Carrà L., **Alberti S.**, Corallini A., Cavazzini L., Fabris G., Aleotti A. and Barbanti-Brodano G. BK virus-induced tumors in hamsters: a morphological, histochemical and ultrastructural study. *Oncology* 40: 427 (1983). IF = 2.613
108. Luini W., Boraschi D., **Alberti S.**, Aleotti A. and Tagliabue A. Morphological characterization of a cell population responsible for natural killer activity. *Immunology*, 43: 663 (1981). IF = 3.735
109. **Alberti S.**, Boraschi D., Luini W. and Tagliabue A. Effects of in vivo treatments with Cyclosporin-A on mouse cell-mediated immune responses. *Int. J. Immunopharmacol.*, 3: 357 (1981). (Now “International Immunopharmacology”) IF = 2.711
110. Grossi M.P., Meneguzzi G., Chenciner N., Corallini A., Poli F., Altavilla G., **Alberti S.**, Milanese G. and Barbanti-Brodano G. Lack of association between BK virus and ependymomas, malignant tumors of pancreatic islets, osteosarcomas and other human tumors. *Intervirology*, 15: 10 (1981). IF = 1.773

**Peer reviewed articles (Oct. 2018) = 110**

**Total IF (Oct. 2018) = 599.689**

**Average IF per article = 5.452**

<b>Total Citations</b>	<b>3002</b>
<b>Average Citations per Article</b>	<b>27.54</b>
<b>Hirsch (H) index (Feb. 2017)</b>	<b>30</b>

### **Work address**

Prof. Saverio Alberti, MD, PhD  
 Unit of Medical Genetics  
 Department of Biomedical Sciences  
 University of Messina  
 University Hospital “G. Martino”  
 via Consolare Valeria  
 98125 Messina, Italy

Phone: (+39) 090-221.3375

Mobile: (+39) 347-3445.123

Skype: saverioalberti

E-mail: [salberti@unime.it](mailto:salberti@unime.it)